13.11
-1.19(-8.32%)
Currency In USD
| Previous Close | 14.3 |
| Open | 12.61 |
| Day High | 13.57 |
| Day Low | 12.59 |
| 52-Week High | 18.29 |
| 52-Week Low | 8.24 |
| Volume | 5.52M |
| Average Volume | 591,472 |
| Market Cap | 653.35M |
| PE | -3.58 |
| EPS | -3.66 |
| Moving Average 50 Days | 10.5 |
| Moving Average 200 Days | 12.05 |
| Change | -1.19 |
If you invested $1000 in Mineralys Therapeutics, Inc. (MLYS) since IPO date, it would be worth $730.75 as of March 12, 2025 at a share price of $13.475. Whereas If you bought $1000 worth of Mineralys Therapeutics, Inc. (MLYS) shares 1 year ago, it would be worth $1,047.82 as of March 12, 2025 at a share price of $13.475.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock
GlobeNewswire Inc.
18 hours ago
RADNOR, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (O
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewswire Inc.
Mar 10, 2025 8:01 PM GMT
RADNOR, Pa., March 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (O
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
GlobeNewswire Inc.
Mar 10, 2025 11:00 AM GMT
– Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg placebo-adjusted reduction (p-value < 0.0001) assessed by automated office blood pressure at week 6 –– Launc